Pedro Henrique Almeida Fraiman

Dr. Pedro Henrique Almeida Fraiman

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
OBOrlando G. P. Barsottini
Orlando G. P. Barsottini
MMMarianna Pinheiro Moraes de Moraes
Marianna Pinheiro Moraes de Moraes
PFPedro Henrique Almeida Fraiman
Pedro Henrique Almeida Fraiman
VMVictor Hugo Rocha Marussi
Victor Hugo Rocha Marussi
ASAlexander Wagner Silva De Souza
Alexander Wagner Silva De Souza
MSMariana Spitz
Mariana Spitz
Sjogren's syndrome (SS) is a complex autoimmune disease characterized by lymphocytic infiltration of salivary and lacrimal glands, resulting in sicca symptoms. Additionally, SS presents with neurological manifestations that significantly impact the nervous system. This review aims to provide a comprehensive overview of the neurological aspects of SSj, covering both the peripheral and central nervous system involvement, while emphasizing diagnosis, treatment, and prognosis.

28 October 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
PFPedro Henrique Almeida Fraiman
Pedro Henrique Almeida Fraiman
JMJoão Paulo Maia‐De‐Oliveira
João Paulo Maia‐De‐Oliveira
MMManuel Moreira‐Neto
Manuel Moreira‐Neto
CGClecio Godeiro‐Junior
Clecio Godeiro‐Junior

5 May 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
PFPedro Henrique Almeida Fraiman
Pedro Henrique Almeida Fraiman
CTCarolina Militão Teixeira
Carolina Militão Teixeira
JOJuliano César Dantas DE Oliveira
Juliano César Dantas DE Oliveira
TSThadeu Alexandre Paulino DE Sousa
Thadeu Alexandre Paulino DE Sousa
MMManuel Moreira-Neto
Manuel Moreira-Neto
CGClecio de Oliveira Godeiro-Junior
Clecio de Oliveira Godeiro-Junior

27 August 2025 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
MCMurilo Marmori Cruccioli
Murilo Marmori Cruccioli
PCPedro Henrique Teixeira Carneiro
Pedro Henrique Teixeira Carneiro
JPJorge Ferreira Jasmineiro Pitanga
Jorge Ferreira Jasmineiro Pitanga
CFCamila Carneiro Ferreira
Camila Carneiro Ferreira
RLRegina Carneiro Leão
Regina Carneiro Leão
FSFilipe P. Sarmento
Filipe P. Sarmento
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.

5 May 2023 in Practical Neurology
Verified
Journal Article
Closed access
PDF file
TCTácio Luis Cavalcante Coradine
Tácio Luis Cavalcante Coradine
LGLucas de Oliveira Cantaruti Guida
Lucas de Oliveira Cantaruti Guida
PFPedro Henrique Almeida Fraiman
Pedro Henrique Almeida Fraiman
ASAdrialdo José Santos
Adrialdo José Santos
JPJosé Luiz Pedroso
José Luiz Pedroso
OBOrlando G P Barsottini
Orlando G P Barsottini
A 56-year-old woman developed progressive subacute lower limb weakness with sensory and autonomic abnormalities. She had received a living-donor kidney transplantation 21 years before for end-stage chronic kidney disease and took mycophenolate mofetil and prednisolone. MR scan of the spinal cord showed bilateral cauda equina gadolinium enhancement and MR scan of the brain showed enhancing nodular hyperintensities in the internal capsule and globus pallidus. Cerebrospinal fluid (CSF) showed a pleocytosis with extremely low glucose, and positive DNA-PCR for Epstein-Barr virus. Her condition worsened despite empirically guided antimicrobial treatment. CSF immunophenotyping later identified mature, clonal B lymphocytes of large size, expressing CD19, CD20, CD200 antigens, and kappa light chain immunoglobulin, with absent CD5 and CD10 expression. We diagnosed a myeloradiculopathy from a monomorphic post-transplant lymphoproliferative disorder. This condition occurs after kidney transplantation and falls on the lymphoma spectrum. We review its clinical features, diagnosis and management.

1 August 2019 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MCMatheus Augusto Araújo Castro
Matheus Augusto Araújo Castro
PFPedro Henrique Almeida Fraiman
Pedro Henrique Almeida Fraiman
CGClecio de Oliveira Godeiro-Junior
Clecio de Oliveira Godeiro-Junior